Lipofilling Agent Identification via In Vitro Adipocyte Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-aging treatments for the face primarily focus on surface texture and volume replacement, but fail to adequately address pan-facial subcutis lipoatrophy, or the loss of supportive fat beneath the dermis, which is a significant aspect of facial aging.
Innovation Solution
A method for characterizing and identifying compounds that regulate lipofilling activity in adipose tissue, specifically targeting the face, by using in vitro assays to measure lipid accumulation, cell viability, and gene expression in preadipocyte cultures from different anatomical sites and age groups, to develop tailored lipofilling agents that increase supportive fat, maintaining a youthful appearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current anti-aging treatments focus on surface texture and volume replacement, then surface microtexture smoothing and wrinkle reduction are improved, but pan-facial subcutis lipoatrophy remains inadequately addressed
Solution Approach 1:
The patent segments the anti-aging treatment into distinct functional components: surface-level treatments (chemical resurfacing, lasers) and deep tissue treatments (lipofilling). This segmentation allows each treatment to target specific aging aspects appropriately, with lipofilling specifically addressing subcutis fat loss while other treatments address surface concerns.
Solution Approach 2:
The patent applies local quality by using autologous fat grafts that are harvested from specific body areas and processed to contain varying proportions of adipocytes, preadipocytes, and stromal vascular fraction. This creates a tailored composition that can be specifically applied to address pan-facial subcutis lipoatrophy while maintaining compatibility with surface-level treatments.
2Duration of action of moving object
If autologous fat transfer is used for volume replacement, then deeper lines and wrinkles are improved, but long-term success is limited without enrichment for adipocyte-derived stem cells
Solution Approach 1:
The patent applies preliminary action by pre-processing the harvested fat through centrifugation and filtration to enrich it with adipocyte-derived stem cells before injection. This preliminary enrichment step ensures that the graft contains a higher concentration of regenerative cells, which promotes long-term survival and integration of the fat graft in the subcutis layer.
Solution Approach 2:
The patent changes the compositional parameters of the fat graft by controlling the differentiation state of adipose tissue. By harvesting fat at specific stages of adipose development and processing it to maintain multipotent cells in an undifferentiated or partially differentiated state, the graft achieves optimal balance between immediate volume replacement and long-term regenerative capacity.
3Quantity of substance
If stem cell differentiation is stimulated to enhance adipocyte number and lipid accumulation, then lipofilling activity is improved, but caution is needed due to multipotent nature
Solution Approach 1:
The patent applies dynamics by allowing controlled differentiation of adipose-derived stem cells within the graft over time. The graft is designed to undergo dynamic changes: initially providing volume through mature adipocytes, then progressively differentiating multipotent cells into functional adipocytes in situ. This dynamic process ensures reliable, staged development of lipofilling activity without requiring complete pre-differentiation.
Solution Approach 2:
The patent uses the extracellular matrix and signaling molecules present in the harvested adipose tissue as intermediaries to regulate stem cell differentiation. These natural mediators provide controlled cues that guide multipotent cells to differentiate into adipocytes at appropriate rates, ensuring reliable lipofilling activity while maintaining safety through biocompatible signaling pathways.
Data Source
AI summary
A method is provided for characterizing a lipofilling agent causing increased lipofilling activity in adipose tissue from a target body area. Such a method can include obtaining a plurality of distinct preadipocyte cultures taken from a plurality of distinct body areas of an individual, exposing the plurality of distinct preadipocyte cultures to a plurality of potential lipofilling agents, culturing the plurality of distinct preadipocyte cultures through differentiation to form a plurality of distinct adipocyte cultures, measuring a degree of lipofilling activity of adipocytes from each of the plurality of distinct adipocyte cultures, and quantifying the measured lipofilling activity across the plurality of distinct adipocyte cultures to identify a lipofilling agent causing increased lipofilling activity in adipose tissue from the target body area as compared to adipose tissue in the non-target body area.